P 101Alternative Names: P-101
Latest Information Update: 23 Oct 2008
At a glance
- Originator Potomac Pharma
- Class Antipsychotics
- Mechanism of Action Alpha 2 adrenergic receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 09 Nov 2004 Phase-II clinical trials in Schizophrenia in USA (unspecified route)